Adverse systemic reaction to benznidazole.
نویسندگان
چکیده
Benznidazole, drug of choice for Chagas disease (CD), has been associated with a high incidence of adverse reactions that can become serious, necessitating discontinuation of the drug. We describe the case of a Bolivian patient living in Spain for 9 years, who, following treatment with benznidazole for CD in indeterminate chronic phase, presented with fever, skin lesions, digestive symptoms, general malaise, and laboratory abnormalities. After the discontinuation of benznidazole and, the intake of antihistamines and systemic corticosteroids, the patient presented a complete resolution of the symptoms. Optimization of dose strategies and development of more effective, and better-tolerated drugs is advisable.
منابع مشابه
Benznidazole-related adverse drug reactions and their relationship to serum drug concentrations in patients with chronic chagas disease.
For treating Chagas disease (CD), a current worldwide health problem, only benznidazole and nifurtimox have been approved to be used. In both cases, unwanted drug-related adverse events (ADRs) are frequent when these drugs are used in adults in the chronic stage. The main objective of this study was to establish benznidazole ADRs and their relationship to serum concentrations in patients with c...
متن کاملمقایسه تأثیر واکسنهای PCECVو PVRVدر بروز عوارض موضعی و منتشر « کارآزمایی بالینی دو سو کور »
Background: The World Health Organization (WHO) has recommended the cell culture based rabies vaccines have no significant side effects. PVRV is a type of cell culture based vaccine, which is used for human rabies vaccination in Iran. Because PVRV is produced by a single source provider; other cell-culture derived vaccines, PCECV, has recently been used for vaccination. Methods: In this dou...
متن کاملButhionine sulfoximine increases the toxicity of nifurtimox and benznidazole to Trypanosoma cruzi.
l-Buthionine (S,R)-sulfoximine (BSO) increased the toxicity of nifurtimox and benznidazole toward the epimastigote, trypomastigote, and amastigote forms of Trypanosoma cruzi. BSO at 500 muM decreased total glutathione-derived thiols by 70 to 80% in 48 h. In epimastigotes, 500 muM BSO decreased the concentration of nifurtimox needed to inhibit constant growth of the parasites by 50%, from 14.0 t...
متن کاملToxic Profile of Benznidazole in Patients with Chronic Chagas Disease: Risk Factors and Comparison of the Product from Two Different Manufacturers.
Benznidazole is considered the first-line treatment option against Chagas disease. The major drawback of benznidazole is its toxicity profile. The main objectives of this study were to describe the adverse events (AEs) in patients with chronic Chagas disease treated with benznidazole, determine the risk factors involved and compare the toxic profiles of two different preparations of the drug fr...
متن کاملSafety of benznidazole use in the treatment of chronic Chagas' disease.
OBJECTIVES To assess the safety of benznidazole use in adult patients with chronic Chagas' disease. METHODS The Naranjo algorithm was applied to classify the causality of adverse drug reactions (ADRs). RESULTS In total, 190 patients were treated with benznidazole over a period of 4-180 days (mean 58.90 ± 36.54 days) with a dose of 50-500 mg/day (221.33 ± 57.16 mg/day). Of the 190 patients t...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Revista da Sociedade Brasileira de Medicina Tropical
دوره 50 1 شماره
صفحات -
تاریخ انتشار 2017